1189TiP Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)
| Autor: | Spigel, D.R., Garrido Lopez, P., Cousin, S., Cheema, P.K., Rodríguez, L.M., Garassino, M.C., Kijewska, M., Majumdar, A., Theti, D.S., Roy-Ghanta, S., Ballas, M., Reck, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1092-S1092 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|